(CercleFinance.com) – The Danish pharmaceutical company Novo Nordisk announces that the United States FDA has extended the indication of its flagship drug Wegovy for the reduction of the risks of major adverse cardiovascular events (MACE).
This indication includes cardiovascular death, non-fatal heart attack (myocardial infarction), or non-fatal stroke in adults who are overweight or obese and have established cardiovascular disease.
This decision was based on cardiovascular results from the SELECT trial, which demonstrated that Wegovy statistically significantly reduced the risk of MACE by 20% compared to placebo when added to standard treatment.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
